119 related articles for article (PubMed ID: 8522572)
1. CYFRA 21-1 determination in patients with non-small cell lung cancer: clinical utility for the detection of recurrences.
Niklinski J; Furman M; Rapellino M; Chyczewski L; Laudanski J; Oliaro A; Ruffini E
J Cardiovasc Surg (Torino); 1995 Oct; 36(5):501-4. PubMed ID: 8522572
[TBL] [Abstract][Full Text] [Related]
2. Diagnostic and prognostic value of the new tumour marker CYFRA 21-1 in patients with squamous cell lung cancer.
Niklinski J; Furman M; Chyczewska E; Chyczewski L; Rogowski F; Laudanski J
Eur Respir J; 1995 Feb; 8(2):291-4. PubMed ID: 7538933
[TBL] [Abstract][Full Text] [Related]
3. Preoperative CYFRA 21-1 level as a prognostic indicator in resected nonsmall cell lung cancer.
Niklinski J; Burzykowski T; Niklinska W; Laudanski J; Chyczewski L; Rapellino M; Furman M
Eur Respir J; 1998 Dec; 12(6):1424-8. PubMed ID: 9877503
[TBL] [Abstract][Full Text] [Related]
4. Tissue polypeptide specific antigen (tps) and cytokeratin 19 fragment (CYFRA 21.1) immunoradiometric assay in non small cell lung cancer evaluation.
Giovanella L; Ceriani L; Bandera M; Rimoldi R; Beghé B; Roncari G
Q J Nucl Med; 1995 Dec; 39(4):285-9. PubMed ID: 8624791
[TBL] [Abstract][Full Text] [Related]
5. Cytokeratin 19 fragment CYFRA 21-1 compared with carcinoembryonic antigen, squamous cell carcinoma antigen and neuron-specific enolase in lung cancer. Results of an international multicentre study.
Ebert W; Dienemann H; Fateh-Moghadam A; Scheulen M; Konietzko N; Schleich T; Bombardieri E
Eur J Clin Chem Clin Biochem; 1994 Mar; 32(3):189-99. PubMed ID: 7518259
[TBL] [Abstract][Full Text] [Related]
6. Cyfra 21-1 as a biologic marker of non-small cell lung cancer. Evaluation of sensitivity, specificity, and prognostic role.
Wieskopf B; Demangeat C; Purohit A; Stenger R; Gries P; Kreisman H; Quoix E
Chest; 1995 Jul; 108(1):163-9. PubMed ID: 7541742
[TBL] [Abstract][Full Text] [Related]
7. CYFRA 21-1 in the early diagnosis of recurrent disease in non small cell lung carcinomas (NSCLC).
Stieber P; Zimmermann A; Reinmiedl J; Müller C; Hoffmann H; Dienemann H
Anticancer Res; 1999; 19(4A):2665-8. PubMed ID: 10470216
[TBL] [Abstract][Full Text] [Related]
8. Analysis of tumor markers in the cytological fluid obtained from computed tomography-guided needle aspiration biopsy for the diagnosis of non-small cell lung cancer.
Hong YJ; Hur J; Lee HJ; Nam JE; Kim YJ; Kim HS; Kim HY; Kim SK; Chang J; Kim JH; Chung KY; Choi BW; Choe KO
J Thorac Oncol; 2011 Aug; 6(8):1330-5. PubMed ID: 21847061
[TBL] [Abstract][Full Text] [Related]
9. [The importance of the tumor marker CYFRA 21-1 in patients with lung cancer after surgery or chemotherapy].
Zissimopoulos A; Stellos K; Permenopoulou V; Petrakis G; Theodorakopoulos P; Baziotis N; Thalassinos N
Hell J Nucl Med; 2007; 10(1):62-6. PubMed ID: 17450257
[TBL] [Abstract][Full Text] [Related]
10. Serum tumor marker CYFRA 21-1 in the diagnostics of NSCLC lung cancer.
Pavićević R; Milicić J; Bubanović G; Supe S
Coll Antropol; 1998 Dec; 22(2):629-35. PubMed ID: 9887620
[TBL] [Abstract][Full Text] [Related]
11. CYFRA 21-1 determination in patients with esophageal squamous cell carcinoma: clinical utility for detection of recurrences.
Kawaguchi H; Ohno S; Miyazaki M; Hashimoto K; Egashira A; Saeki H; Watanabe M; Sugimachi K
Cancer; 2000 Oct; 89(7):1413-7. PubMed ID: 11013352
[TBL] [Abstract][Full Text] [Related]
12. Does the assessment of serum markers in patients with lung cancer aid in the clinical decision making process?
Ebert W; Muley T; Drings P
Anticancer Res; 1996; 16(4B):2161-8. PubMed ID: 8694537
[TBL] [Abstract][Full Text] [Related]
13. Cytokeratin fragment 19 (CYFRA 21-1) as a tumor marker in non-small cell lung cancer.
Huang MS; Jong SB; Lin MS; Chong IW; Tsai MS; Lin HC; Hwang JJ
Kaohsiung J Med Sci; 1996 Feb; 12(2):62-8. PubMed ID: 8709175
[TBL] [Abstract][Full Text] [Related]
14. Serum fragment of cytokeratin subunit 19 measured by CYFRA 21-1 immunoradiometric assay as a marker of lung cancer.
Pujol JL; Grenier J; Daurès JP; Daver A; Pujol H; Michel FB
Cancer Res; 1993 Jan; 53(1):61-6. PubMed ID: 7677981
[TBL] [Abstract][Full Text] [Related]
15. [Cyfra 21-1 new marker for non-small cell lung cancer].
Nikliński J; Furman M; Chyczewski L; Chyczewska E; Rogowski F; Jaroszewicz E
Pneumonol Alergol Pol; 1994; 62(5-6):227-32. PubMed ID: 7522725
[TBL] [Abstract][Full Text] [Related]
16. Monitoring cytokeratin fragment 19 (CYFRA 21-1) serum levels for early prediction of recurrence of adenocarcinoma and squamous cell carcinoma in the lung after surgical resection.
Yeh JJ; Liu FY; Hsu WH; Wang JJ; Ho ST; Kao A
Lung; 2002; 180(5):273-9. PubMed ID: 12489021
[TBL] [Abstract][Full Text] [Related]
17. Tumour markers CEA, NSE, SCC, TPA and CYFRA 21.1 in resectable non-small cell lung cancer.
Foa P; Fornier M; Miceli R; Seregni E; Santambrogio L; Nosotti M; Cataldo I; Sala M; Caldiera S; Bombardieri E
Anticancer Res; 1999; 19(4C):3613-8. PubMed ID: 10629660
[TBL] [Abstract][Full Text] [Related]
18. [Clinical usefulness of serum assay of EIA-CYFRA 21-1 in lung cancer].
Satoh H; Yagyu H; Sumi M; Ishikawa H; Hamada M; Suyama T; Naitoh T; Inoue M; Saitoh T; Uchida Y
Gan To Kagaku Ryoho; 1994 May; 21(6):795-9. PubMed ID: 7514388
[TBL] [Abstract][Full Text] [Related]
19. Utility of serum cytokeratin 19 fragment (CYFRA 21-1) and carcinoembryonic antigen (CEA) as tumour markers for non-small cell lung cancer.
Chantapet P; Riantawan P; Lebnak P; Getngern P
J Med Assoc Thai; 2000 Apr; 83(4):383-91. PubMed ID: 10808698
[TBL] [Abstract][Full Text] [Related]
20. Prognostic value of CYFRA 21-1, TPS and CEA in different histologic types of non-small cell lung cancer.
Nisman B; Amir G; Lafair J; Heching N; Lyass O; Peretz T; Barak V
Anticancer Res; 1999; 19(4C):3549-52. PubMed ID: 10629651
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]